Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (Businesswire) - Mar 14, 2023 - "KZR-261 has shown dose-proportional exposure and no signs of accumulation or altered pharmacokinetics with repeated dosing. There have been no consistent patterns of safety signals. Kezar plans to report safety and dose escalation data from this trial in the second half of 2023."
P1 data • Oncology • Solid Tumor
|